Latest News

Better Safety Profile Observed With Istradefylline Over Amantadine Extended-Release and COMT Inhibitors
Better Safety Profile Observed With Istradefylline Over Amantadine Extended-Release and COMT Inhibitors

June 25th 2024

Although the data used predated 2019, istradefylline was associated with a statistically significant lower odds of the overall incidence of treatment-emergent adverse events than other adjunctive therapies for Parkinson disease.

Patients With Essential Tremor Report High Levels of Dissatisfaction With Treatment Options
Patients With Essential Tremor Report High Levels of Dissatisfaction With Treatment Options

June 24th 2024

Jeffrey M. Dayno, MD  (Credit: LinkedIn)
FDA Approves Pitolisant for Excessive Daytime Sleepiness in Pediatric Narcolepsy

June 24th 2024

This Week on NeurologyLive® — June 24, 2024
This Week on NeurologyLive® — June 24, 2024

June 24th 2024

Coverage of SLEEP 2024

Get the latest data and clinical news updates, as well as interviews with experts, straight from the conference floor of SLEEP 2024.

SLEEP 2024

Conference Coverage

View All
Better Safety Profile Observed With Istradefylline Over Amantadine Extended-Release and COMT Inhibitors
Better Safety Profile Observed With Istradefylline Over Amantadine Extended-Release and COMT Inhibitors

June 25th 2024

Patients With Essential Tremor Report High Levels of Dissatisfaction With Treatment Options
Patients With Essential Tremor Report High Levels of Dissatisfaction With Treatment Options

June 24th 2024

Charbel Moussa, MBBS, PhD
Disease-Modifying Therapies for Dementia in Movement Disorders: Charbel Moussa, MBBS, PhD

June 24th 2024

Kelly Papesh, DNP, APRN, FNP-BC
Overcoming Barriers in Communication for Patient Disclosure in Movement Disorders: Kelly Papesh, DNP, APRN, FNP-BC

June 24th 2024

Video Series
Video Interviews
Podcasts

Most Recent

© 2024 MJH Life Sciences

All rights reserved.